Neovascularization in the human heart is associated with expression of VEGF-A and its receptors Fit-1 (VEGFR-1) and KDR (VEGFR-2). Results from cardiomyopexy in ischemic cardiomyopathy

Angiogenesis

Volumn 3, Issue 4, 1999, Pages 345-351

  Waltenberger, Johannes ^a   Kranz, Andrea ^a   Beyer, Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Cardiomyopexy; Immunohistochemistry; Indirect myocardial revascularization; KDR; Vascular endothelial growth factor A (VEGF A)

Indexed keywords

MUSCULUS;

EID: 2242423544     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026585900398     Document Type: Article

References (33)

1. Beyer M. Cardiomyopexy - An update of an indirect myocardial revascularization procedure. Z Kardiol 1997; 86: 125-132.
2. Beyer M, Gerber J, Waltenberger J et al. Die indirekte Myokard-revaskularisation: erste klinische Ergebnisse an 17 Patienten. Z Kardiol 1997; 86(Supplement 2): 215.
3. Beyer M, Hoffer H, Eggeling T et al. Free skeletal muscle transplantation to an infarction area: An experimental study in the dog. Microsurg 1993; 14: 125-9.
4. Ferrara N, DavisSmyth T. The biology of vascular endothelial growth factor. Endocrine Rev 1997; 18: 4-25.
5. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269: 26988-95.
6. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
7. Banai S, Shweiki D, Pinson A et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: Implications for coronary angiogenesis. Cardiovasc Res 1994; 28: 1176-9.
8. Banai S, Jaklitsch MT, Shou M et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89: 2183-9.
9. Pearlman JD, Hibberd MG, Chuang ML et al. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nature Med 1995; 1: 1085-9.
10. Harada K, Friedman M, Lopez JJ et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996; 270: H1791-H1802.
11. Isner JM. Arterial gene transfer of naked DNA for therapeutic angiogenesis: Early clinical results. Advan Drug Delivery Rev 1998; 30: 185-197.
12. Baumgartner I, Pieczek A, Manor O et al. Constitutive expression of phVEGF(165) after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-23.
13. Vale PR, Losordo DW, Symes JF, Isner JM. Gene therapy for myocardial angiogenesis. Circulation 1998; 98: 1-322.
14. Waltenberger J. Therapeutic angiogenesis in the heart using peptide growth factors: Angiogenesis research entering clinical trials. Angiogenesis 1998; 2: 115-7.
15. Öberg C, Waltenberger J, Claesson-Welsh L, Welsh M. Expression of protein tyrosine kinases in islet cells: Possible role of the flk-1 receptor for β-cell maturation from duct cells. Growth Factors 1994; 10: 115-126.
16. Key JA, Kergin FG, Martineau. A method of supplementing the coronary circulation by a jejunal pedicle graft. J Thorac Surg 1954; 28: 320-8.
17. Moran RE. Revascularization of the heart by tubed pedicle graft of skin and subcutaneous tissue. Plast Rec Surg 1952; 10: 295-303.
18. O'Shaugnessy L, Sloan P, Watson F. Surgical revascularization of the heart. Lancet 1938; 1: 617-25.
19. Li J, Brown LF, Hibberd MG et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270: H1803-11.
20. Olofsson B, Pajusola K, Kaipainen A et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996; 93: 2576-81.
21. Berse B, Brown LF, van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-20.
22. Dvorak HF, Sioussat TM, Brown LF et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 1991; 174: 1275-8.
23. Qu-Hong JA, Senger DR, Dvorak HF, Dvorak AM. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. J Histochem Cytochem 1995; 43: 381-9.
24. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845-8.
25. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26: 86-91.
26. Brown LF, Berse B, Jackman RW et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53: 4727-35.
27. Liu Y, Cox S, Morita T, Kourembanas S. Hypoxia regulates VEGF gene expression in endothelial cells: Identification of a 5′enhancer. Circ Res 1995; 77: 638-43.
28. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94: 1647-54.
29. Giraudo E, Primo L, Audero E, Gerber HP et al. Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998; 273: 22128-35.
30. Clauss M, Weich H, Breier G et al. The vascular endothelial growth factor receptor FLT-1 mediates biological activities: Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996; 271: 17629-34.
31. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349-54.
32. Lazarous D, Scheinowitz M, Shou M et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995; 91: 145-53.
33. Laham RJ, Sellke FW, Edelman ER et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypas surgery: Results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999; 100: 1865-71.